Voie d'immunisation et séquence d'administration de l ... - TEL
Voie d'immunisation et séquence d'administration de l ... - TEL Voie d'immunisation et séquence d'administration de l ... - TEL
tel-00827710, version 1 - 29 May 2013 example, in our model we observed both the positive and negative effects of adjuvant depending on the timing of its delivery. While we proposed a delayed adjuvant delivery to overcome this complication, other studies demonstrated that co-administration with antigen may lead to a more robust priming. West et al. showed in an in vitro model that co-administration of LPS with Ovalbumin immune complexes enhanced antigen uptake and presentation by remodeling the actin cytoskeleton. In contrast, delayed delivery of adjuvant after antigen exposure did not promote the same effect (West et al., 2004). Importantly, this effect is only transient and overall, a down-regulation of antigen capture was observed upon adjuvant exposure, similar to what has been described in our work and by other teams (Wilson et al., 2006; Weck et al., 2007). This transient enhancement of antigen uptake has been demonstrated to be dependent on TLR-signaling. 1) Optimal timing depends on the TLR ligand The downregulation of antigen uptake observed upon adjuvant delivery was first thought to be due to DC maturation and be dependent on TLR trigerring. However, it appears to also depend on the type of TLR ligand used for stimulation, despite the fact that all of them were shown to induce DC maturation in vivo (Schwarz et al., 2003). Weck and colleagues demonstrated that DCs matured after stimulation with TLR3 or TL4 ligands were not able to take up apoptotic cells efficiently, as compared to DCs matured with TLR7/8 or TLR2 (Weck et al., 2007). This dichotomy parallels the intracellular pathways engaged by TLR ligands. TLR7/8 and TLR2 trigger a Myd88-dependent pathway, whereas TLR3 induces a TRIF- dependent pathway. TLR4 can trigger both pathways (Figure 5). Consequently, it has been suggested that TLR3 and TLR4 ligands could be co-administered as adjuvants for antigens that do not need to be engulfed, such as peptide, whereas TLR7/8 or TLR2 ligands would be used for antigens that required phagocytosis to be presented. Another possibility to work around these heterogeneous functions is to delay the administration of TLR3 or TLR4 ligand as previously discussed. 2) Optimal timing depends on receptor engaged Recently, Tirapu et al. focused on the inhibition of antigen uptake following poly I:C delivery and demonstrated that it was not actually due to TLR trigerring (Tirapu et al., 2009). Instead, there was a competition between poly I:C and antigen to interact with scavenger receptors. Interestingly, while poly I:C stimulation reduced uptake through scavenger receptor, it did not affect endocytosis by mannose receptor, which is known to be crucial for Ovalbumin 168
tel-00827710, version 1 - 29 May 2013 endocytosis. Compared to the study performed by Weck and colleagues, the reduction of antigen uptake in this study was not associated with less efficient priming. Weck at al. studied uptake of apoptotic cells by human DCs whereas Tirapu et al. performed their experiments with mouse DCs and soluble Ovalbumin. These different systems and antigens may explain the functional variations observed, specifically the fact that soluble antigen and dying cells are not engulfed via the same pathways, which are also differentially regulated by adjuvant treatment (Burgdorf et al., 2007). These differences highlight the importance of considering several critical parameters when combining an antigen and an adjuvant for therapy: (i) the antigen type, (ii) the receptor(s) and the pathway(s) engaged by the antigen, (iii) the adjuvant type and (iv) the receptor(s) and the pathway(s) engaged by the adjuvant. The understanding of antigen presentation pathways, as well as intracellular pathways trigerred by the adjuvant of interest, are necessary to optimize vaccination strategies. D. Applications in clinical studies 1) Translation into human treatments The use of adjuvant is important in order to boost immune responses. However the pattern of TLR expression is not always similar between mice and humans. The best example is CpG, the ligand for TLR9. This receptor is expressed by cDCs, pDCs and B cells in mice, but only on pDCs and B cells in humans (Kadowaki et al., 2001). From what has been discussed regarding the potential requirement for DCs to detect antigen and adjuvant in the same time, the different expression patterns might constitute a huge difference in overall responsiveness. This may explain why some treatments with CpG that provided nice results in mice, were just not as good in humans (Schmidt, 2007). These differences are crucial and must be taken in account when developing an experimental mouse model to address questions of cross- presentation and antigen/adjuvant delivery. 2) Manipulating DCs for vaccination (a) Use of IFN-treated DCs Treatment with type I IFN represents a strategy for inducing the maturation of DCs ex vivo prior to their administration into patients, an approach often taken in the case of DC-based vaccines. Interestingly, treatment with different cytokines ex vivo skewed the differentiation Page 169 of 256
- Page 117 and 118: tel-00827710, version 1 - 29 May 20
- Page 119 and 120: tel-00827710, version 1 - 29 May 20
- Page 121 and 122: tel-00827710, version 1 - 29 May 20
- Page 123 and 124: tel-00827710, version 1 - 29 May 20
- Page 125 and 126: tel-00827710, version 1 - 29 May 20
- Page 127 and 128: tel-00827710, version 1 - 29 May 20
- Page 129 and 130: tel-00827710, version 1 - 29 May 20
- Page 131 and 132: tel-00827710, version 1 - 29 May 20
- Page 133 and 134: tel-00827710, version 1 - 29 May 20
- Page 135 and 136: tel-00827710, version 1 - 29 May 20
- Page 137 and 138: tel-00827710, version 1 - 29 May 20
- Page 139 and 140: tel-00827710, version 1 - 29 May 20
- Page 141 and 142: tel-00827710, version 1 - 29 May 20
- Page 143 and 144: tel-00827710, version 1 - 29 May 20
- Page 145 and 146: tel-00827710, version 1 - 29 May 20
- Page 147 and 148: tel-00827710, version 1 - 29 May 20
- Page 149 and 150: tel-00827710, version 1 - 29 May 20
- Page 151 and 152: tel-00827710, version 1 - 29 May 20
- Page 153 and 154: tel-00827710, version 1 - 29 May 20
- Page 155 and 156: tel-00827710, version 1 - 29 May 20
- Page 157 and 158: tel-00827710, version 1 - 29 May 20
- Page 159 and 160: tel-00827710, version 1 - 29 May 20
- Page 161 and 162: tel-00827710, version 1 - 29 May 20
- Page 163 and 164: tel-00827710, version 1 - 29 May 20
- Page 165 and 166: tel-00827710, version 1 - 29 May 20
- Page 167: tel-00827710, version 1 - 29 May 20
- Page 171 and 172: tel-00827710, version 1 - 29 May 20
- Page 173 and 174: tel-00827710, version 1 - 29 May 20
- Page 175 and 176: tel-00827710, version 1 - 29 May 20
- Page 177 and 178: tel-00827710, version 1 - 29 May 20
- Page 179 and 180: tel-00827710, version 1 - 29 May 20
- Page 181 and 182: tel-00827710, version 1 - 29 May 20
- Page 183 and 184: tel-00827710, version 1 - 29 May 20
- Page 185 and 186: tel-00827710, version 1 - 29 May 20
- Page 187 and 188: tel-00827710, version 1 - 29 May 20
- Page 189 and 190: tel-00827710, version 1 - 29 May 20
- Page 191 and 192: tel-00827710, version 1 - 29 May 20
- Page 193 and 194: tel-00827710, version 1 - 29 May 20
- Page 195 and 196: tel-00827710, version 1 - 29 May 20
- Page 197 and 198: tel-00827710, version 1 - 29 May 20
- Page 199 and 200: tel-00827710, version 1 - 29 May 20
- Page 201 and 202: tel-00827710, version 1 - 29 May 20
- Page 203 and 204: tel-00827710, version 1 - 29 May 20
- Page 205 and 206: tel-00827710, version 1 - 29 May 20
- Page 207 and 208: tel-00827710, version 1 - 29 May 20
- Page 209 and 210: tel-00827710, version 1 - 29 May 20
- Page 211 and 212: tel-00827710, version 1 - 29 May 20
- Page 213 and 214: tel-00827710, version 1 - 29 May 20
- Page 215 and 216: tel-00827710, version 1 - 29 May 20
- Page 217 and 218: tel-00827710, version 1 - 29 May 20
tel-00827710, version 1 - 29 May 2013<br />
example, in our mo<strong>de</strong>l we observed both the positive and negative effects of adjuvant<br />
<strong>de</strong>pending on the timing of its <strong>de</strong>livery.<br />
While we proposed a <strong>de</strong>layed adjuvant <strong>de</strong>livery to overcome this complication, other studies<br />
<strong>de</strong>monstrated that co-administration with antigen may lead to a more robust priming. West <strong>et</strong><br />
al. showed in an in vitro mo<strong>de</strong>l that co-administration of LPS with Ovalbumin immune<br />
complexes enhanced antigen uptake and presentation by remo<strong>de</strong>ling the actin cytoskel<strong>et</strong>on. In<br />
contrast, <strong>de</strong>layed <strong>de</strong>livery of adjuvant after antigen exposure did not promote the same effect<br />
(West <strong>et</strong> al., 2004). Importantly, this effect is only transient and overall, a down-regulation of<br />
antigen capture was observed upon adjuvant exposure, similar to what has been <strong>de</strong>scribed in<br />
our work and by other teams (Wilson <strong>et</strong> al., 2006; Weck <strong>et</strong> al., 2007). This transient<br />
enhancement of antigen uptake has been <strong>de</strong>monstrated to be <strong>de</strong>pen<strong>de</strong>nt on TLR-signaling.<br />
1) Optimal timing <strong>de</strong>pends on the TLR ligand<br />
The downregulation of antigen uptake observed upon adjuvant <strong>de</strong>livery was first thought to<br />
be due to DC maturation and be <strong>de</strong>pen<strong>de</strong>nt on TLR trigerring. However, it appears to also<br />
<strong>de</strong>pend on the type of TLR ligand used for stimulation, <strong>de</strong>spite the fact that all of them were<br />
shown to induce DC maturation in vivo (Schwarz <strong>et</strong> al., 2003). Weck and colleagues<br />
<strong>de</strong>monstrated that DCs matured after stimulation with TLR3 or TL4 ligands were not able to<br />
take up apoptotic cells efficiently, as compared to DCs matured with TLR7/8 or TLR2 (Weck<br />
<strong>et</strong> al., 2007). This dichotomy parallels the intracellular pathways engaged by TLR ligands.<br />
TLR7/8 and TLR2 trigger a Myd88-<strong>de</strong>pen<strong>de</strong>nt pathway, whereas TLR3 induces a TRIF-<br />
<strong>de</strong>pen<strong>de</strong>nt pathway. TLR4 can trigger both pathways (Figure 5). Consequently, it has been<br />
suggested that TLR3 and TLR4 ligands could be co-administered as adjuvants for antigens<br />
that do not need to be engulfed, such as pepti<strong>de</strong>, whereas TLR7/8 or TLR2 ligands would be<br />
used for antigens that required phagocytosis to be presented. Another possibility to work<br />
around these h<strong>et</strong>erogeneous functions is to <strong>de</strong>lay the administration of TLR3 or TLR4 ligand<br />
as previously discussed.<br />
2) Optimal timing <strong>de</strong>pends on receptor engaged<br />
Recently, Tirapu <strong>et</strong> al. focused on the inhibition of antigen uptake following poly I:C <strong>de</strong>livery<br />
and <strong>de</strong>monstrated that it was not actually due to TLR trigerring (Tirapu <strong>et</strong> al., 2009). Instead,<br />
there was a comp<strong>et</strong>ition b<strong>et</strong>ween poly I:C and antigen to interact with scavenger receptors.<br />
Interestingly, while poly I:C stimulation reduced uptake through scavenger receptor, it did not<br />
affect endocytosis by mannose receptor, which is known to be crucial for Ovalbumin<br />
168